Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Cancer Immunotherapy-An Overview.
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward.
Immunotherapy in Head and Neck Cancer.
The Impact of the Tumor Microenvironment on the Effect of IL-1ß Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward.
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 Sep 12; 6(9):100803.
View in:
PubMed
subject areas
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Humans
Lung Neoplasms
Molecular Targeted Therapy
Mutation
Precision Medicine
Protein Kinase Inhibitors
authors with profiles
Ravi Salgia